Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to
mediate the mechanism of immune tolerance and provide immune homeostasis …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Background Combined diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state
(HHS) secondary to immune checkpoint inhibitors (ICIs) is extremely rarely reported among …

Simple Summary Malignant neoplasms are currently one of the main causes of morbidity
and mortality worldwide, posing a major public health challenge. However, recent advances …

Combination checkpoint inhibitor (CPI) and chemotherapy is an effective and safe treatment
strategy for patients with untreated classic Hodgkin lymphoma. Recent studies of …

Pediatric papillary thyroid carcinomas (PPTCs) exhibit high inter-tumor heterogeneity and
currently lack widely adopted recurrence risk stratification criteria. Hence, we propose a …

Immunotherapy with immune checkpoint inhibitors (ICI) is increasingly employed in
oncology. National and international endocrine and oncologic scientific societies have …

Background Immune checkpoint inhibitors (ICIs) cause a variety of immune-related adverse
events (irAEs). Among them, thyroid dysfunction is most frequently observed. Patients with …

Immune checkpoint inhibitors (ICIs) are associated with multiple endocrine side effects,
including thyroid disfunctions. In addition, the efficacy and safety profiles of ICIs in the …

Abstract Purpose of Review Immune checkpoint inhibitor (ICI) use has been on the rise for
treatment of many different malignancies. Subsequently, more has been learned about …